Theramex

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.

Retrieved on: 
Tuesday, October 10, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Patient, Menopause, Generic drug, Pharmaceutical industry, Theramex

Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan.

Key Points: 
  • Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan.
  • The transaction is subject to customary regulatory and anti-trust approvals.
  • “As we continue to strengthen our commitment to women’s health and improve our patients access to high quality treatments, we are excited to acquire new products to expand our Menopause portfolio.” - Rob Stewart, CEO of Theramex.

Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼in the European Economic Area, the United Kingdom, Australia and Brazil

Retrieved on: 
Monday, March 20, 2023
Women, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Consumer, Other Health, Partnership, Osteoporosis, Woman, Abaloparatide, Patient, European Economic Area, Fracture, Risk, United Kingdom, Dietary supplement, Radius, Theramex

Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil.

Key Points: 
  • Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil.
  • “Theramex has again shown its commitment to women and the care and good management of bone health, by adding this important product to our Osteoporosis franchise.
  • Our aligned, strategic vision of bringing effective solutions to the right patient gives us unwavering confidence in this partnership.
  • We look forward to seeing the continued global expansion of abaloparatide to patients with osteoporosis worldwide.” - Scott Briggs, CEO of Radius

Global Hormone Replacement Therapy Market 2022: A $25+ Billion Market by 2027 - Industry Trends, Growth, Impact of Inflation, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Health, Pharmaceutical, Disease, Ageing, Pfizer, HRT, National Library of Medicine classification, Osteoporosis, UN, Hormone replacement therapy, Health Canada, Availability, Menopause, Flash, Estradiol, Fatigue, Risk, Muscle, Thyroid, Drug development, Degenerative disease, Woman, Weight gain, Patient, Prevalence, Mindfulness, National library, Uterus, Hypothyroidism, Prescription, Disorder, Theramex, Progesterone, Growth hormone, Incidence, Breast cancer, Pharmaceutical industry, Birth control, Frontier, Type, Growth, Testosterone

The "Hormone Replacement Therapy Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hormone Replacement Therapy Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Hormone Replacement Therapy Market is expected to reach US$ 25.09 Billion by 2027 from US$ 18.04 Billion in 2022, growing with a CAGR of 6.82% during 2022-2027.
  • According to the UN, the global population will grow by 8.5 billion in 2030 and 9.7 billion in 2050.
  • Based on Type, hormone replacement therapy is categorized into Estrogen, Human Growth, Thyroid, Testosterone, and Progestogen.

ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Retrieved on: 
Tuesday, June 28, 2022
SIX Swiss Exchange, Patient, Gynaecology, Marketing, Company, Hormone, Birth, MHRA, Royal commission, Birth certificate, Quality of life, Urology, Osteoporosis, Drug development, Nasdaq, Pregnancy, Coronavirus, Uterine fibroid, NDA, Security (finance), FDA, European, ABT, Woman, Anemia, Nephrology Dialysis Transplantation, Uterus, SEC, Risk, Central Research Laboratories, Solution, CEO, Report, New Drug Application, Linzagolix, European Commission, Menopause, Investor, Private Securities Litigation Reform Act, Health, U.S. Securities and Exchange Commission, NASDAQ, Mental health, Bloating, Review, Anxiety, Fertility, Adult, Pain, Theramex, Endometriosis, Gonadotropin-releasing hormone, PDUFA, Medicines and Healthcare products Regulatory Agency, Medical device, Pharmaceutical industry, Birth control, EU, Kissei, UF

Yselty is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.

Key Points: 
  • Yselty is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.
  • The MHRA approval follows the granting of marketing authorization by the European Commission earlier in June 2022.
  • For women with UF who cannot or do not want to take hormones, Yselty is the first and only approved oral GnRH antagonist with a non-hormonal dosing option.
  • As the first and only approved GnRH antagonist to offer flexible dosing options with and without additional hormonal therapy, we hope to redefine care for women suffering from uterine fibroids.

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Symptoms of Uterine Fibroids

Retrieved on: 
Friday, June 17, 2022
Medical Supplies, Health, Consumer, Women, Pharmaceutical, Biotechnology, Solution, Gonadotropin-releasing hormone, Fertility, Uterine fibroid, Nasdaq, CHMP, Menopause, Contraindication, Endometriosis, Urology, Theramex, Central Research Laboratories, Pregnancy, Linzagolix, SIX Swiss Exchange, Kissei, Birth, Committee, Physician, Health, Nephrology Dialysis Transplantation, European Commission, European Directive on Traditional Herbal Medicinal Products, Partnership, Adult, Patient, Life, Committee for Medicinal Products for Human Use, Osteoporosis, ABT, Woman, EC, Pharmaceutical industry, UF, EU

The European Commission (EC) has granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.

Key Points: 
  • The European Commission (EC) has granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.
  • The EC decision follows the Committee for Medicinal Products for Human Use (CHMP) confirmation of positive opinion in April 2022.
  • Linzagolix is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.
  • Uterine Fibroids affect 25% of women within reproductive age, many with severe symptoms requiring surgery.

Theramex Launches Non-hormonal Femarelle® on the 12th of May

Retrieved on: 
Monday, May 9, 2022
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, Birth, Gynecological Endocrinology, Fertility, HRT, Congress, Woman, Patient, Menopause, Health, Osteoporosis, Life, Solution, International Society, Awareness, Health insurance, Medical device, Theramex

Theramex will be joining the 20th International Society of Gynecological Endocrinology (ISGE) congress from the 11th-14th May in Florence, Italy.

Key Points: 
  • Theramex will be joining the 20th International Society of Gynecological Endocrinology (ISGE) congress from the 11th-14th May in Florence, Italy.
  • Theramex are very proud to introduce Femarelle which Theramex will commercialize in Italy, France, Spain, Germany, UK, Belgium, Poland and Australia.
  • Femarelle is a non-hormonal food supplement developed to help women manage symptoms in perimenopause, with Femarelle Rejuvenate1; menopause, with Femarelle Recharge2; and post-menopause, with Femarelle Unstoppable3.
  • As Camilla Harder Hartvig, Chief Commercial Officer at Theramex says "we are delighted to add Femarelle to our already broad portfolio of prescription products to treat menopause symptoms.

ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Retrieved on: 
Monday, April 25, 2022
EMA, Hormone, Nasdaq, Pain, Uterine fibroid, Osteoporosis, Woman, Menopause, Security (finance), NASDAQ, Risk, Patient, PDUFA, Review, Royal commission, UF, U.S. Securities and Exchange Commission, European Commission, Central Research Laboratories, Urology, FDA, Health, Investor, Drug development, Food, Private Securities Litigation Reform Act, Syneos Health, CCO, Theramex, Linzagolix, Endometriosis, Pregnancy, Company, Solution, Contract research organization, Food and Drug Administration, Committee, CEO, European Medicines Agency, Birth certificate, SIX Swiss Exchange, CRO, SEC, Coronavirus, New Drug Application, CHMP, Gonadotropin-releasing hormone, Gynaecology, Clinical trial, EC, Birth, Fertility, Pharmaceutical industry, Kissei

The positive CHMP opinion, which was initially adopted on December 16, 2021, was confirmed at the April 2022 CHMP meeting following further review of the linzagolix marketing authorization application.

Key Points: 
  • The positive CHMP opinion, which was initially adopted on December 16, 2021, was confirmed at the April 2022 CHMP meeting following further review of the linzagolix marketing authorization application.
  • European Commission decisions are valid in the European Union Member States, as well as Iceland, Norway, and Liechtenstein.
  • ObsEva has entered into a licensing agreement with Theramex to support the commercialization and market introduction of linzagolix in Europe.
  • Linzagolix has completed clinical trial development for the treatment of uterine fibroids and is currently in late-stage clinical development for the treatment of pain associated with endometriosis.

ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix

Retrieved on: 
Thursday, February 10, 2022
NASDAQ, Health, New Drug Application, Patient, SIX Swiss Exchange, Quality of life, CEO, Birth certificate, Risk, Pregnancy, SEC, Review, Solution, EDELWEISS, Security (finance), Endometriosis, Uterine fibroid, Clinical trial, GLOBE, Nasdaq, Pain, Osteoporosis, Food and Drug Administration, Woman, Linzagolix, Gynaecology, FDA, Birth, Partnership, PDUFA, Gonadotropin-releasing hormone, Fertility, Private Securities Litigation Reform Act, Coronavirus, Investor, Menopause, Report, Drug development, Urology, U.S. Securities and Exchange Commission, Syneos Health, Pharmaceutical industry, Theramex

GENEVA, Switzerland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced a strategic licensing agreement with Theramex, a leading global pharmaceutical company specializing in women’s health, to support the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia.

Key Points: 
  • Theramex is a proven global leader in womens health and the ideal partner to maximize the opportunity for linzagolix in key international markets, said Brian OCallaghan, CEO of ObsEva.
  • This Theramex partnership in Europe, together with our relationship with Syneos Health for the commercialization of linzagolix in the U.S., provides ObsEva with a strong foundation to realize the full value of the linzagolix program.
  • This agreement strengthens our portfolio and we look forward to deploying our extensive global commercial infrastructure to unlock linzagolixs potential.
  • Under the terms of the agreement, ObsEva is entitled to receive royalties of a mid-thirties percentage on commercial sales, which includes the cost of goods sold to Theramex.

Theramex Australia Enters Partnership With Endoceutics For Intrarosa® For The Treatment Of Postmenopausal Vulvovaginal Atrophy

Retrieved on: 
Monday, February 14, 2022
Medical Devices, Medical Supplies, Women, FDA, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Health, Pain, Dyspareunia, Vaginal discharge, Woman, Prasterone, VVA, Menopause, Dehydroepiandrosterone, Personal lubricant, DHEA, Pharmaceutical industry, Birth control, Theramex, Theramex, Endoceutics, THERAMEX, ENDOCEUTICS

Theramex, a leading global speciality pharmaceutical company dedicated to womens health, has expanded its original agreement with Endoceutics to commercialise Intrarosa (prasterone) in Australia.

Key Points: 
  • Theramex, a leading global speciality pharmaceutical company dedicated to womens health, has expanded its original agreement with Endoceutics to commercialise Intrarosa (prasterone) in Australia.
  • Until now we have been helping women in Europe with VVA, and now we are delighted to be able to do the same in Australia.
  • Intrarosa provides an important new treatment option to relieve VVA symptoms and maintain vaginal health without significant release of oestrogens in the blood.
  • Since July 2019, it has been commercialised by Theramex in Europe, after the agreement with Endoceutics.

Theramex Announces Licensing Agreement with ObsEva for the Commercialisation of Linzagolix for the Treatment of Uterine Fibroids

Retrieved on: 
Thursday, February 10, 2022
Biotechnology, Women, Consumer, Health, Pharmaceutical, Patient, SIX Swiss Exchange, Birth certificate, Pregnancy, Abdominal pain, Leiomyoma, Anti–vascular endothelial growth factor therapy, Solution, Low back pain, Endometriosis, Uterine fibroid, Osteoporosis, Uterus, Woman, Linzagolix, Constipation, Birth, Nasdaq, Partnership, Gonadotropin-releasing hormone, Fertility, Physician, Fibroid, Menopause, Drug development, Pharmaceutical industry, Theramex, Theramex, ObsEva, THERAMEX, OBSEVA

Linzagolix is a GnRH receptor antagonist for the treatment of uterine fibroids.

Key Points: 
  • Linzagolix is a GnRH receptor antagonist for the treatment of uterine fibroids.
  • ObsEva is an ideal partner for Theramex given their focus on developing novel treatments to meet unmet medical needs of women suffering from uterine fibroids, endometriosis, and pre-term labour.
  • Uterine Fibroids affect 25% of women within reproductive age, many with severe symptoms requiring surgery.
  • By licensing Linzagolix we can potentially offer a new treatment option for physicians in managing women with uterine fibroids to provide symptomatic relief and delay or avoid surgery.